Published in Clin Transl Med on April 11, 2013
Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One (2013) 0.97
Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol (2013) 0.91
IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. Int J Hepatol (2014) 0.83
Current management of patients with hepatocellular carcinoma. World J Hepatol (2015) 0.82
Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol (2015) 0.80
Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol (2015) 0.78
Faldaprevir for the treatment of hepatitis C. Int J Mol Sci (2015) 0.76
Hepatitis C virus genotypes in Myanmar. World J Gastroenterol (2016) 0.75
IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World J Hepatol (2013) 0.75
Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virol (2015) 0.75
Automating crystallographic structure solution and refinement of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2013) 0.75
Roles of lipoprotein receptors in the entry of hepatitis C virus. World J Hepatol (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med (2004) 8.12
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
A phylogenetically conserved stem-loop structure at the 5' border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation. J Virol (1999) 3.13
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis (2012) 2.41
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol (2012) 2.34
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int (2012) 1.79
New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting. Clin Infect Dis (2012) 1.54
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat (2012) 1.50
Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets (2006) 1.49
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother (2012) 1.48
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol (2012) 1.28
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat (2012) 1.19
Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res (2013) 1.16
Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol (2006) 1.16
Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol (2011) 1.07
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs (2013) 1.05
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol (2007) 1.02
How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int (2013) 1.01
Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One (2011) 1.00
Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res (2013) 0.96
TMC435 for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2012) 0.91
Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol (2004) 0.90
Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses (2012) 0.89
A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol (2007) 0.87
Progress toward development of a hepatitis C vaccine with broad shoulders. Sci Transl Med (2011) 0.86
Diagnosis and management of telaprevir-associated rash. Gastroenterol Hepatol (N Y) (2011) 0.85
Sustained virologic response: is this equivalent to cure of chronic hepatitis C? Hepatology (2013) 0.84
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. J Med Chem (2009) 0.83
Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. Clin Infect Dis (2012) 0.83
Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver Int (2008) 0.81
Hepatitis C virus and hepatocellular carcinoma. Biology (Basel) (2013) 0.80
Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol (2010) 0.79
Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem (2009) 0.79
Natural history of HCV infection. Hepatol Int (2012) 0.76
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol (2011) 3.88
Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer (2005) 3.69
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology (2005) 3.26
Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res (2005) 3.19
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet (2011) 3.19
Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med (2005) 3.18
Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases. Clin Gastroenterol Hepatol (2007) 3.13
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol (2003) 2.90
Risk assessment for delayed hemorrhagic complication of colonic polypectomy: polyp-related factors and patient-related factors. Gastrointest Endosc (2006) 2.78
Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol (2006) 2.75
Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology (2009) 2.59
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int (2005) 2.46
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res (2003) 2.44
Single-balloon versus double-balloon endoscopy for achieving total enteroscopy: a randomized, controlled trial. Gastrointest Endosc (2011) 2.39
Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology (2003) 2.38
A randomized controlled trial evaluating the usefulness of a transparent hood attached to the tip of the colonoscope. Am J Gastroenterol (2006) 2.35
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Tissue damage of different submucosal injection solutions for EMR. Gastrointest Endosc (2005) 2.27
De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol (2013) 2.22
Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int (2008) 2.15
Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol (2003) 2.13
Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc (2006) 2.13
Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer (2011) 2.09
Factors affecting the accuracy of endoscopic transpapillary sampling methods for bile duct cancer. Dig Endosc (2013) 2.09
Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology (2003) 2.06
Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology (2003) 2.05
Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc (2009) 2.05
Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol (2006) 2.05
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Efficacy of stone density on noncontrast computed tomography in predicting the outcome of extracorporeal shock wave lithotripsy for patients with pancreatic stones. Pancreas (2015) 1.97
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res (2008) 1.91
Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology (2006) 1.90
Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology (2008) 1.88
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer (2006) 1.87
Endoscopic submucosal dissection using flexknife. J Clin Gastroenterol (2006) 1.83
Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol (2009) 1.80
Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology (2002) 1.79
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol (2008) 1.78
Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study. Gastrointest Endosc (2008) 1.74
New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71
Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med (2003) 1.70
Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res (2009) 1.70
Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 1.70
Detection of common bile duct stones: comparison between endoscopic ultrasonography, magnetic resonance cholangiography, and helical-computed-tomographic cholangiography. Eur J Radiol (2005) 1.68
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res (2005) 1.65
UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res (2004) 1.62
Efficacy and safety of low-pressured and short-time dilation in endoscopic papillary balloon dilation for bile duct stone removal. J Gastroenterol Hepatol (2007) 1.60
Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol (2004) 1.56
Clinical utility of intraductal US to decrease early recurrence rate of common bile duct stones after endoscopic papillotomy. J Gastroenterol Hepatol (2008) 1.56
Endoscopic papillary balloon dilation for the management of bile duct stones in patients 85 years of age and older. Gastrointest Endosc (2008) 1.56
The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res (2008) 1.56
Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology (2002) 1.55
Right-side shift of colorectal adenomas with aging. Gastrointest Endosc (2006) 1.55
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res (2005) 1.51
Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology (2005) 1.50
Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci (2008) 1.49
Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol (2010) 1.49
Diagnostic value of magnetic resonance cholangiopancreatography for clinically suspicious spontaneous passage of bile duct stones. J Gastroenterol Hepatol (2007) 1.49
Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res (2009) 1.49
Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med (2004) 1.48
Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer (2009) 1.47
Impact of introduction of wire-guided cannulation in therapeutic biliary endoscopic retrograde cholangiopancreatography. J Gastroenterol Hepatol (2011) 1.47
Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum (2007) 1.46
Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. Dig Liver Dis (2010) 1.45
Heterogeneous staining in the liver parenchyma after the injection of perflubutane microbubble contrast agent. Ultrasound Med Biol (2012) 1.45
Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn's disease. Dig Dis Sci (2013) 1.44
Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut (2007) 1.43
HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene (2002) 1.43
Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens (2002) 1.43
Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. J Gastroenterol (2010) 1.43
Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology (2007) 1.42
Early gastric cancer shows different associations with adipose tissue volume depending on histological type. Gastric Cancer (2008) 1.42
MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun (2011) 1.41
Preoperative assessment of longitudinal extension of cholangiocarcinoma with peroral video-cholangioscopy: a prospective study. Dig Endosc (2013) 1.41
Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients. Liver Int (2008) 1.40
Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol (2008) 1.40
Old age is associated with increased severity of complications in endoscopic biliary stone removal. Dig Endosc (2014) 1.39
Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol (2007) 1.39
The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene (2005) 1.37
Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int (2002) 1.37
Efficacy and safety of the covered Wallstent in patients with distal malignant biliary obstruction. Gastrointest Endosc (2005) 1.32
Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology (2003) 1.31
Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol (2008) 1.31
Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology (2006) 1.31
Cholecystitis after metallic stent placement in patients with malignant distal biliary obstruction. Clin Gastroenterol Hepatol (2006) 1.31
Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology (2010) 1.31
Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun (2007) 1.30